Skip to main content
Infection and Immunity logoLink to Infection and Immunity
. 1996 Sep;64(9):3833–3844. doi: 10.1128/iai.64.9.3833-3844.1996

NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

J A Tine 1, D E Lanar 1, D M Smith 1, B T Wellde 1, P Schultheiss 1, L A Ware 1, E B Kauffman 1, R A Wirtz 1, C De Taisne 1, G S Hui 1, S P Chang 1, P Church 1, M R Hollingdale 1, D C Kaslow 1, S Hoffman 1, K P Guito 1, W R Ballou 1, J C Sadoff 1, E Paoletti 1
PMCID: PMC174300  PMID: 8751936

Abstract

The highly attenuated NYVAC vaccinia virus strain has been utilized to develop a multiantigen, multistage vaccine candidate for malaria, a disease that remains a serious global health problem and for which no highly effective vaccine exists. Genes encoding seven Plasmodium falciparum antigens derived from the sporozoite (circumsporozoite protein and sporozoite surface protein 2), liver (liver stage antigen 1), blood (merozoite surface protein 1, serine repeat antigen, and apical membrane antigen 1), and sexual (25-kDa sexual-stage antigen) stages of the parasite life cycle were inserted into a single NYVAC genome to generate NYVAC-Pf7. Each of the seven antigens was expressed in NYVAC-Pf7-infected culture cells, and the genotypic and phenotypic stability of the recombinant virus was demonstrated. When inoculated into rhesus monkeys, NYVAC-Pf7 was safe and well tolerated. Antibodies that recognize sporozoites, liver, blood, and sexual stages of P. falciparum were elicited. Specific antibody responses against four of the P.falciparum antigens (circumsporozoite protein, sporozoite surface protein 2, merozoite surface protein 1, and 25-kDa sexual-stage antigen) were characterized. The results demonstrate that NYVAC-Pf7 is an appropriate candidate vaccine for further evaluation in human clinical trials.

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggarwal A., Kumar S., Jaffe R., Hone D., Gross M., Sadoff J. Oral Salmonella: malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells. J Exp Med. 1990 Oct 1;172(4):1083–1090. doi: 10.1084/jem.172.4.1083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ballou W. R., Hoffman S. L., Sherwood J. A., Hollingdale M. R., Neva F. A., Hockmeyer W. T., Gordon D. M., Schneider I., Wirtz R. A., Young J. F. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. 1987 Jun 6;1(8545):1277–1281. doi: 10.1016/s0140-6736(87)90540-x. [DOI] [PubMed] [Google Scholar]
  3. Barr P. J., Green K. M., Gibson H. L., Bathurst I. C., Quakyi I. A., Kaslow D. C. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med. 1991 Nov 1;174(5):1203–1208. doi: 10.1084/jem.174.5.1203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brochier B., Kieny M. P., Costy F., Coppens P., Bauduin B., Lecocq J. P., Languet B., Chappuis G., Desmettre P., Afiademanyo K. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature. 1991 Dec 19;354(6354):520–522. doi: 10.1038/354520a0. [DOI] [PubMed] [Google Scholar]
  5. Brockmeier S. L., Lager K. M., Tartaglia J., Riviere M., Paoletti E., Mengeling W. L. Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses. Vet Microbiol. 1993 Dec;38(1-2):41–58. doi: 10.1016/0378-1135(93)90074-h. [DOI] [PubMed] [Google Scholar]
  6. Burkot T. R., Da Z. W., Geysen H. M., Wirtz R. A., Saul A. Fine specificities of monoclonal antibodies against the Plasmodium falciparum circumsporozoite protein: recognition of both repetitive and non-repetitive regions. Parasite Immunol. 1991 Mar;13(2):161–170. doi: 10.1111/j.1365-3024.1991.tb00272.x. [DOI] [PubMed] [Google Scholar]
  7. Caspers P., Gentz R., Matile H., Pink J. R., Sinigaglia F. The circumsporozoite protein gene from NF54, a Plasmodium falciparum isolate used in malaria vaccine trials. Mol Biochem Parasitol. 1989 Jun 15;35(2):185–189. doi: 10.1016/0166-6851(89)90121-7. [DOI] [PubMed] [Google Scholar]
  8. Chakrabarti S., Robert-Guroff M., Wong-Staal F., Gallo R. C., Moss B. Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature. 1986 Apr 10;320(6062):535–537. doi: 10.1038/320535a0. [DOI] [PubMed] [Google Scholar]
  9. Chang S. P., Hui G. S., Kato A., Siddiqui W. A. Generalized immunological recognition of the major merozoite surface antigen (gp195) of Plasmodium falciparum. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6343–6347. doi: 10.1073/pnas.86.16.6343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chang S. P., Kramer K. J., Yamaga K. M., Kato A., Case S. E., Siddiqui W. A. Plasmodium falciparum: gene structure and hydropathy profile of the major merozoite surface antigen (gp195) of the Uganda-Palo Alto isolate. Exp Parasitol. 1988 Oct;67(1):1–11. doi: 10.1016/0014-4894(88)90002-1. [DOI] [PubMed] [Google Scholar]
  11. Collins W. E., Pye D., Crewther P. E., Vandenberg K. L., Galland G. G., Sulzer A. J., Kemp D. J., Edwards S. J., Coppel R. L., Sullivan J. S. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg. 1994 Dec;51(6):711–719. doi: 10.4269/ajtmh.1994.51.711. [DOI] [PubMed] [Google Scholar]
  12. Coupar B. E., Andrew M. E., Both G. W., Boyle D. B. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur J Immunol. 1986 Dec;16(12):1479–1487. doi: 10.1002/eji.1830161203. [DOI] [PubMed] [Google Scholar]
  13. Cox W. I., Tartaglia J., Paoletti E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology. 1993 Aug;195(2):845–850. doi: 10.1006/viro.1993.1442. [DOI] [PubMed] [Google Scholar]
  14. Cremer K. J., Mackett M., Wohlenberg C., Notkins A. L., Moss B. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science. 1985 May 10;228(4700):737–740. doi: 10.1126/science.2986288. [DOI] [PubMed] [Google Scholar]
  15. Deans J. A., Knight A. M., Jean W. C., Waters A. P., Cohen S., Mitchell G. H. Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol. 1988 Sep;10(5):535–552. doi: 10.1111/j.1365-3024.1988.tb00241.x. [DOI] [PubMed] [Google Scholar]
  16. Delplace P., Bhatia A., Cagnard M., Camus D., Colombet G., Debrabant A., Dubremetz J. F., Dubreuil N., Prensier G., Fortier B. Protein p126: a parasitophorous vacuole antigen associated with the release of Plasmodium falciparum merozoites. Biol Cell. 1988;64(2):215–221. doi: 10.1016/0248-4900(88)90080-9. [DOI] [PubMed] [Google Scholar]
  17. Delplace P., Fortier B., Tronchin G., Dubremetz J. F., Vernes A. Localization, biosynthesis, processing and isolation of a major 126 kDa antigen of the parasitophorous vacuole of Plasmodium falciparum. Mol Biochem Parasitol. 1987 Apr;23(3):193–201. doi: 10.1016/0166-6851(87)90026-0. [DOI] [PubMed] [Google Scholar]
  18. Earl P. L., Hügin A. W., Moss B. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J Virol. 1990 May;64(5):2448–2451. doi: 10.1128/jvi.64.5.2448-2451.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Enders B., Hundt E., Knapp B. Strategies for the development of an antimalarial vaccine. Vaccine. 1992;10(13):920–927. doi: 10.1016/0264-410x(92)90326-f. [DOI] [PubMed] [Google Scholar]
  20. Etlinger H. M., Caspers P., Matile H., Schoenfeld H. J., Stueber D., Takacs B. Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum. Infect Immun. 1991 Oct;59(10):3498–3503. doi: 10.1128/iai.59.10.3498-3503.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Goebel S. J., Johnson G. P., Perkus M. E., Davis S. W., Winslow J. P., Paoletti E. The complete DNA sequence of vaccinia virus. Virology. 1990 Nov;179(1):247-66, 517-63. doi: 10.1016/0042-6822(90)90294-2. [DOI] [PubMed] [Google Scholar]
  22. Good M. F., Saul A., Graves P. M. Malaria vaccines. Biotechnology. 1992;20:69–98. doi: 10.1016/b978-0-7506-9265-6.50010-5. [DOI] [PubMed] [Google Scholar]
  23. Gordon D. M. Malaria vaccines. Infect Dis Clin North Am. 1990 Jun;4(2):299–313. [PubMed] [Google Scholar]
  24. Guerin-Marchand C., Druilhe P., Galey B., Londono A., Patarapotikul J., Beaudoin R. L., Dubeaux C., Tartar A., Mercereau-Puijalon O., Langsley G. A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature. 1987 Sep 10;329(6135):164–167. doi: 10.1038/329164a0. [DOI] [PubMed] [Google Scholar]
  25. Guo P. X., Goebel S., Perkus M. E., Taylor J., Norton E., Allen G., Languet B., Desmettre P., Paoletti E. Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity. J Virol. 1990 May;64(5):2399–2406. doi: 10.1128/jvi.64.5.2399-2406.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hall R., Hyde J. E., Goman M., Simmons D. L., Hope I. A., Mackay M., Scaife J., Merkli B., Richle R., Stocker J. Major surface antigen gene of a human malaria parasite cloned and expressed in bacteria. 1984 Sep 27-Oct 3Nature. 311(5984):379–382. doi: 10.1038/311379a0. [DOI] [PubMed] [Google Scholar]
  27. Herrera M. A., Rosero F., Herrera S., Caspers P., Rotmann D., Sinigaglia F., Certa U. Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum gamma interferon levels with protection. Infect Immun. 1992 Jan;60(1):154–158. doi: 10.1128/iai.60.1.154-158.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Herrera S., Herrera M. A., Perlaza B. L., Burki Y., Caspers P., Döbeli H., Rotmann D., Certa U. Immunization of Aotus monkeys with Plasmodium falciparum blood-stage recombinant proteins. Proc Natl Acad Sci U S A. 1990 May;87(10):4017–4021. doi: 10.1073/pnas.87.10.4017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Herrington D. A., Clyde D. F., Losonsky G., Cortesia M., Murphy J. R., Davis J., Baqar S., Felix A. M., Heimer E. P., Gillessen D. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature. 1987 Jul 16;328(6127):257–259. doi: 10.1038/328257a0. [DOI] [PubMed] [Google Scholar]
  30. Hill A. V., Elvin J., Willis A. C., Aidoo M., Allsopp C. E., Gotch F. M., Gao X. M., Takiguchi M., Greenwood B. M., Townsend A. R. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature. 1992 Dec 3;360(6403):434–439. doi: 10.1038/360434a0. [DOI] [PubMed] [Google Scholar]
  31. Holder A. A., Freeman R. R., Nicholls S. C. Immunization against Plasmodium falciparum with recombinant polypeptides produced in Escherichia coli. Parasite Immunol. 1988 Nov;10(6):607–617. doi: 10.1111/j.1365-3024.1988.tb00248.x. [DOI] [PubMed] [Google Scholar]
  32. Hollingdale M. R., Aikawa M., Atkinson C. T., Ballou W. R., Chen G. X., Li J., Meis J. F., Sina B., Wright C., Zhu J. D. Non-CS pre-erythrocytic protective antigens. Immunol Lett. 1990 Aug;25(1-3):71–76. doi: 10.1016/0165-2478(90)90094-7. [DOI] [PubMed] [Google Scholar]
  33. Hu S. L., Kosowski S. G., Dalrymple J. M. Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature. 1986 Apr 10;320(6062):537–540. doi: 10.1038/320537a0. [DOI] [PubMed] [Google Scholar]
  34. Inselburg J., Bathurst I. C., Kansopon J., Barchfeld G. L., Barr P. J., Rossan R. N. Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: adjuvant effects on induction of protective immunity. Infect Immun. 1993 May;61(5):2041–2047. doi: 10.1128/iai.61.5.2041-2047.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Inselburg J., Bathurst I. C., Kansopon J., Barr P. J., Rossan R. Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: further studies using SERA 1 and MF75.2 adjuvant. Infect Immun. 1993 May;61(5):2048–2052. doi: 10.1128/iai.61.5.2048-2052.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Inselburg J., Bzik D. J., Li W. B., Green K. M., Kansopon J., Hahm B. K., Bathurst I. C., Barr P. J., Rossan R. N. Protective immunity induced in Aotus monkeys by recombinant SERA proteins of Plasmodium falciparum. Infect Immun. 1991 Apr;59(4):1247–1250. doi: 10.1128/iai.59.4.1247-1250.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Kaslow D. C., Isaacs S. N., Quakyi I. A., Gwadz R. W., Moss B., Keister D. B. Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus. Science. 1991 May 31;252(5010):1310–1313. doi: 10.1126/science.1925544. [DOI] [PubMed] [Google Scholar]
  38. Kaslow D. C., Quakyi I. A., Syin C., Raum M. G., Keister D. B., Coligan J. E., McCutchan T. F., Miller L. H. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature. 1988 May 5;333(6168):74–76. doi: 10.1038/333074a0. [DOI] [PubMed] [Google Scholar]
  39. Khusmith S., Charoenvit Y., Kumar S., Sedegah M., Beaudoin R. L., Hoffman S. L. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science. 1991 May 3;252(5006):715–718. doi: 10.1126/science.1827210. [DOI] [PubMed] [Google Scholar]
  40. Klotz F. W., Hadley T. J., Aikawa M., Leech J., Howard R. J., Miller L. H. A 60-kDa Plasmodium falciparum protein at the moving junction formed between merozoite and erythrocyte during invasion. Mol Biochem Parasitol. 1989 Sep;36(2):177–185. doi: 10.1016/0166-6851(89)90190-4. [DOI] [PubMed] [Google Scholar]
  41. Knapp B., Shaw A., Hundt E., Enders B., Küpper H. A. A histidin alanine rich recombinant antigen protects Aotus monkeys from P. falciparum infection. Behring Inst Mitt. 1988 Apr;(82):349–359. [PubMed] [Google Scholar]
  42. Konishi E., Pincus S., Paoletti E., Shope R. E., Burrage T., Mason P. W. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology. 1992 Jun;188(2):714–720. doi: 10.1016/0042-6822(92)90526-u. [DOI] [PubMed] [Google Scholar]
  43. Kumar S., Yadava A., Keister D. B., Tian J. H., Ohl M., Perdue-Greenfield K. A., Miller L. H., Kaslow D. C. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med. 1995 Mar;1(3):325–332. [PMC free article] [PubMed] [Google Scholar]
  44. Lanar D. E., Tine J. A., de Taisne C., Seguin M. C., Cox W. I., Winslow J. P., Ware L. A., Kauffman E. B., Gordon D., Ballou W. R. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect Immun. 1996 May;64(5):1666–1671. doi: 10.1128/iai.64.5.1666-1671.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Li S., Rodrigues M., Rodriguez D., Rodriguez J. R., Esteban M., Palese P., Nussenzweig R. S., Zavala F. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5214–5218. doi: 10.1073/pnas.90.11.5214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Lyon J. A., Haynes J. D., Diggs C. L., Chulay J. D., Haidaris C. G., Pratt-Rossiter J. Monoclonal antibody characterization of the 195-kilodalton major surface glycoprotein of Plasmodium falciparum malaria schizonts and merozoites: identification of additional processed products and a serotype-restricted repetitive epitope. J Immunol. 1987 Feb 1;138(3):895–901. [PubMed] [Google Scholar]
  47. Mackett M., Arrand J. R. Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340. EMBO J. 1985 Dec 1;4(12):3229–3234. doi: 10.1002/j.1460-2075.1985.tb04070.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Mason P. W., Pincus S., Fournier M. J., Mason T. L., Shope R. E., Paoletti E. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology. 1991 Jan;180(1):294–305. doi: 10.1016/0042-6822(91)90034-9. [DOI] [PubMed] [Google Scholar]
  49. Miller L. H., Roberts T., Shahabuddin M., McCutchan T. F. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol. 1993 May;59(1):1–14. doi: 10.1016/0166-6851(93)90002-f. [DOI] [PubMed] [Google Scholar]
  50. Narum D. L., Thomas A. W. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol Biochem Parasitol. 1994 Sep;67(1):59–68. doi: 10.1016/0166-6851(94)90096-5. [DOI] [PubMed] [Google Scholar]
  51. Noya O., Gabaldón Berti Y., Alarcón de Noya B., Borges R., Zerpa N., Urbáez J. D., Madonna A., Garrido E., Jimenéz M. A., Borges R. E. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J Infect Dis. 1994 Aug;170(2):396–402. doi: 10.1093/infdis/170.2.396. [DOI] [PubMed] [Google Scholar]
  52. Nussenzweig V., Nussenzweig R. S. Rationale for the development of an engineered sporozoite malaria vaccine. Adv Immunol. 1989;45:283–334. doi: 10.1016/s0065-2776(08)60695-1. [DOI] [PubMed] [Google Scholar]
  53. Panicali D., Davis S. W., Weinberg R. L., Paoletti E. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A. 1983 Sep;80(17):5364–5368. doi: 10.1073/pnas.80.17.5364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Paoletti E., Lipinskas B. R., Samsonoff C., Mercer S., Panicali D. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A. 1984 Jan;81(1):193–197. doi: 10.1073/pnas.81.1.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Patarroyo M. E., Romero P., Torres M. L., Clavijo P., Moreno A., Martínez A., Rodríguez R., Guzman F., Cabezas E. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature. 1987 Aug 13;328(6131):629–632. doi: 10.1038/328629a0. [DOI] [PubMed] [Google Scholar]
  56. Perkus M. E., Limbach K., Paoletti E. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol. 1989 Sep;63(9):3829–3836. doi: 10.1128/jvi.63.9.3829-3836.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Perkus M. E., Piccini A., Lipinskas B. R., Paoletti E. Recombinant vaccinia virus: immunization against multiple pathogens. Science. 1985 Sep 6;229(4717):981–984. doi: 10.1126/science.2992092. [DOI] [PubMed] [Google Scholar]
  58. Perrin L. H., Merkli B., Loche M., Chizzolini C., Smart J., Richle R. Antimalarial immunity in Saimiri monkeys. Immunization with surface components of asexual blood stages. J Exp Med. 1984 Aug 1;160(2):441–451. doi: 10.1084/jem.160.2.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Phillips R. S. Vaccination against malaria. Immunobiology. 1992 Feb;184(2-3):240–262. doi: 10.1016/S0171-2985(11)80478-X. [DOI] [PubMed] [Google Scholar]
  60. Potocnjak P., Yoshida N., Nussenzweig R. S., Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med. 1980 Jun 1;151(6):1504–1513. doi: 10.1084/jem.151.6.1504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Pye D., Edwards S. J., Anders R. F., O'Brien C. M., Franchina P., Corcoran L. N., Monger C., Peterson M. G., Vandenberg K. L., Smythe J. A. Failure of recombinant vaccinia viruses expressing Plasmodium falciparum antigens to protect Saimiri monkeys against malaria. Infect Immun. 1991 Jul;59(7):2403–2411. doi: 10.1128/iai.59.7.2403-2411.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Rogers W. O., Malik A., Mellouk S., Nakamura K., Rogers M. D., Szarfman A., Gordon D. M., Nussler A. K., Aikawa M., Hoffman S. L. Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9176–9180. doi: 10.1073/pnas.89.19.9176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Sadoff J. C., Ballou W. R., Baron L. S., Majarian W. R., Brey R. N., Hockmeyer W. T., Young J. F., Cryz S. J., Ou J., Lowell G. H. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science. 1988 Apr 15;240(4850):336–338. doi: 10.1126/science.3281260. [DOI] [PubMed] [Google Scholar]
  64. Satchidanandam V., Zavala F., Moss B. Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of Plasmodium berghei. Mol Biochem Parasitol. 1991 Sep;48(1):89–99. doi: 10.1016/0166-6851(91)90167-5. [DOI] [PubMed] [Google Scholar]
  65. Schmitt J. F., Stunnenberg H. G. Sequence and transcriptional analysis of the vaccinia virus HindIII I fragment. J Virol. 1988 Jun;62(6):1889–1897. doi: 10.1128/jvi.62.6.1889-1897.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Schödel F., Wirtz R., Peterson D., Hughes J., Warren R., Sadoff J., Milich D. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J Exp Med. 1994 Sep 1;180(3):1037–1046. doi: 10.1084/jem.180.3.1037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Sedegah M., Hedstrom R., Hobart P., Hoffman S. L. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9866–9870. doi: 10.1073/pnas.91.21.9866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Siddiqui W. A., Tam L. Q., Kramer K. J., Hui G. S., Case S. E., Yamaga K. M., Chang S. P., Chan E. B., Kan S. C. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc Natl Acad Sci U S A. 1987 May;84(9):3014–3018. doi: 10.1073/pnas.84.9.3014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Smith G. L., Murphy B. R., Moss B. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A. 1983 Dec;80(23):7155–7159. doi: 10.1073/pnas.80.23.7155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Szarfman A., Lyon J. A., Walliker D., Quakyi I., Howard R. J., Sun S., Ballou W. R., Esser K., London W. T., Wirtz R. A. Mature liver stages of cloned Plasmodium falciparum share epitopes with proteins from sporozoites and asexual blood stages. Parasite Immunol. 1988 May;10(3):339–351. doi: 10.1111/j.1365-3024.1988.tb00225.x. [DOI] [PubMed] [Google Scholar]
  71. Tartaglia J., Perkus M. E., Taylor J., Norton E. K., Audonnet J. C., Cox W. I., Davis S. W., van der Hoeven J., Meignier B., Riviere M. NYVAC: a highly attenuated strain of vaccinia virus. Virology. 1992 May;188(1):217–232. doi: 10.1016/0042-6822(92)90752-b. [DOI] [PubMed] [Google Scholar]
  72. Tartaglia J., Pincus S., Paoletti E. Poxvirus-based vectors as vaccine candidates. Crit Rev Immunol. 1990;10(1):13–30. [PubMed] [Google Scholar]
  73. Thomas A. W., Waters A. P., Carr D. Analysis of variation in PF83, an erythrocytic merozoite vaccine candidate antigen of Plasmodium falciparum. Mol Biochem Parasitol. 1990 Sep-Oct;42(2):285–287. doi: 10.1016/0166-6851(90)90172-i. [DOI] [PubMed] [Google Scholar]
  74. Tine J. A., Conseil V., Delplace P., De Taisne C., Camus D., Paoletti E. Immunogenicity of the Plasmodium falciparum serine repeat antigen (p126) expressed by vaccinia virus. Infect Immun. 1993 Sep;61(9):3933–3941. doi: 10.1128/iai.61.9.3933-3941.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Valero M. V., Amador L. R., Galindo C., Figueroa J., Bello M. S., Murillo L. A., Mora A. L., Patarroyo G., Rocha C. L., Rojas M. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet. 1993 Mar 20;341(8847):705–710. doi: 10.1016/0140-6736(93)90483-w. [DOI] [PubMed] [Google Scholar]
  76. Vos J. C., Stunnenberg H. G. Derepression of a novel class of vaccinia virus genes upon DNA replication. EMBO J. 1988 Nov;7(11):3487–3492. doi: 10.1002/j.1460-2075.1988.tb03224.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Wachsman M., Aurelian L., Smith C. C., Lipinskas B. R., Perkus M. E., Paoletti E. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. J Infect Dis. 1987 Jun;155(6):1188–1197. doi: 10.1093/infdis/155.6.1188. [DOI] [PubMed] [Google Scholar]
  78. Wachsman M., Luo J. H., Aurelian L., Perkus M. E., Paoletti E. Antigen-presenting capacity of epidermal cells infected with vaccinia virus recombinants containing the herpes simplex virus glycoprotein D, and protective immunity. J Gen Virol. 1989 Sep;70(Pt 9):2513–2520. doi: 10.1099/0022-1317-70-9-2513. [DOI] [PubMed] [Google Scholar]
  79. Wirtz R. A., Ballou W. R., Schneider I., Chedid L., Gross M. J., Young J. F., Hollingdale M., Diggs C. L., Hockmeyer W. T. Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. Exp Parasitol. 1987 Apr;63(2):166–172. doi: 10.1016/0014-4894(87)90158-5. [DOI] [PubMed] [Google Scholar]
  80. Yewdell J. W., Bennink J. R., Smith G. L., Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A. 1985 Mar;82(6):1785–1789. doi: 10.1073/pnas.82.6.1785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Young J. F., Hockmeyer W. T., Gross M., Ballou W. R., Wirtz R. A., Trosper J. H., Beaudoin R. L., Hollingdale M. R., Miller L. H., Diggs C. L. Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine. Science. 1985 May 24;228(4702):958–962. doi: 10.1126/science.2988125. [DOI] [PubMed] [Google Scholar]
  82. Yuen L., Moss B. Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc Natl Acad Sci U S A. 1987 Sep;84(18):6417–6421. doi: 10.1073/pnas.84.18.6417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Zarling J. M., Morton W., Moran P. A., McClure J., Kosowski S. G., Hu S. L. T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses. 1986 Sep 25-Oct 1Nature. 323(6086):344–346. doi: 10.1038/323344a0. [DOI] [PubMed] [Google Scholar]
  84. Zhu J., Hollingdale M. R. Structure of Plasmodium falciparum liver stage antigen-1. Mol Biochem Parasitol. 1991 Oct;48(2):223–226. doi: 10.1016/0166-6851(91)90117-o. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES